Loading…
Ascendis Pharma A/S is projected to rise to $352.75 by 2027, a +30% move from its current price of $270.45. ASND is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $264.80 | $270.52 | $276.36 | +0.03% |
| Jul 14 | $262.53 | $270.59 | $278.89 | +0.05% |
| Jul 15 | $260.82 | $270.65 | $280.86 | +0.08% |
| Jul 16 | $259.39 | $270.72 | $282.55 | +0.10% |
| Jul 17 | $258.15 | $270.79 | $284.05 | +0.13% |
| Jul 18 | $257.04 | $270.86 | $285.42 | +0.15% |
| Jul 19 | $256.03 | $270.93 | $286.69 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $256.03 | $270.93 | $286.69 | +0.18% |
| Week 2 | $250.54 | $271.40 | $294.00 | +0.35% |
| Week 3 | $246.51 | $271.88 | $299.86 | +0.53% |
| Week 4 | $243.24 | $272.36 | $304.98 | +0.71% |
| Week 5 | $240.43 | $272.84 | $309.62 | +0.89% |
| Week 6 | $237.97 | $273.33 | $313.94 | +1.06% |
| Week 7 | $235.76 | $273.81 | $318.00 | +1.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ascendis Pharma A/S is a biotechnology company that operates as a biopharmaceutical company focused on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
The company was incorporated in 2006 and is based in Hellerup, Denmark.
In the Healthcare sector, Ascendis Pharma A/S is described by its product portfolio and ongoing development programs, positioning itself as a specialty biopharmaceutical player with a diversified pipeline targeting endocrine disorders and oncology.
Ascendis Pharma A/S (ASND) is a healthcare stock with a current price of $261.58 and a market capitalization of $17.15B. It is ranked 654 by market size. The near-term price outlook shows a neutral stance for 2026, while a multi-year forecast depicts substantial upside through 2030 and beyond.
The 2026 forecast lists a min of $202.99, an avg of $261.58, and a max of $365.53, with an ROI of 0 and a neutral sentiment. From 2027 onward, the forecast envisions rising averages and positive returns, culminating in a max price of $6,737.61 by 2050 and an ROI of 1,331%.
Key long-run targets in the forecast include a 2030 average of $593.04 (ROI 126.7%), a 2040 average of $1,720.40 (ROI 557.7%), and a 2050 average of $3,743.21 (ROI 1,331%), all signaling a bullish trajectory through mid-century and beyond.
A major floor 33.5% below — a decisive break under it would weaken the trend.
The nearest floor, 23.9% below — buyers have tended to step in here.
Price is pressing into resistance (2.5% away) — a breakout level to watch.
A major ceiling 19.3% above — clearing it would confirm fresh momentum.
Key ASND support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ASND market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $271.59 | Sell | $271.42 | Sell |
| MA 10 | $269.14 | Buy | $266.13 | Buy |
| MA 20 | $250.39 | Buy | $255.66 | Buy |
| MA 50 | $238.34 | Buy | $242.98 | Buy |
| MA 100 | $234.84 | Buy | $234.73 | Buy |
| MA 200 | $222.18 | Buy | $221.30 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.40 | Neutral |
| Stoch RSI (14) | 56.33 | Neutral |
| CCI (20) | 67.30 | Neutral |
| Williams %R (14) | -13.68 | Info |
| MACD (12,26,9) | 2.27 | Buy |
| ROC (12) | 13.35 | Buy |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 86.32 | Sell |
| TRIX (15) | 0.60 | Buy |
| Awesome (5,34) | 31.91 | Buy |
| Ultimate (7,14,28) | 63.20 | Neutral |
| Momentum (10) | 8.87 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 274.86 | Sell |
| ADX (14) | 29.67 | Buy |
| ATR (14) | 4.87 | Info |
The 30-day technical picture shows a bullish sentiment with a relative strength index around the high end of typical, at RSI 14 of 70.
The stock trades above the 50-day simple moving average (SMA50) at $231.49 and above the 200-day simple moving average (SMA200) at $218.62, indicating an upward trend.
Support is noted at $205.81, while near-term resistance sits at $261.58. The 30-day price range spans from $221.31 to $309.18, reflecting upside potential with limited downside risk in the immediate window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $202.99 | $270.45 | $367.30 | 0% | Neutral | |
| $286.48 | $352.75 | $455.87 | +30% | Bullish | |
| $362.93 | $456.52 | $607.83 | +69% | Bullish | |
| $403.82 | $516.97 | $704.69 | +91% | Bullish | |
| $428.76 | $557.43 | $775.08 | +106% | Bullish | |
| $494.09 | $651.42 | $921.69 | +141% | Bullish | |
| $505.67 | $675.40 | $970.71 | +150% | Bullish | |
| $542.27 | $733.11 | $1,068.78 | +171% | Bullish | |
| $680.51 | $930.61 | $1,374.65 | +244% | Bullish | |
| $753.58 | $1,041.87 | $1,557.94 | +285% | Bullish | |
| $1,044.63 | $1,516.91 | $2,388.36 | +461% | Bullish | |
| $2,054.73 | $3,239.82 | $5,504.28 | +11.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $202.99 | $270.45 | $328.32 | +0.00% |
| August 2026 | $237.97 | $279.29 | $335.43 | +3.27% |
| September 2026 | $234.52 | $276.73 | $335.27 | -0.92% |
| October 2026 | $239.60 | $284.04 | $346.68 | +2.64% |
| November 2026 | $247.88 | $295.03 | $362.32 | +3.87% |
| December 2026 | $248.94 | $297.37 | $367.30 | +0.80% |
Click any year to see its month-by-month ASND forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Ascendis Pharma A/S's 2026 outlook centres on $270.45, within a $202.99 to $367.30 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, ASND could reach as high as $455.87, with a base case around $352.75 and support toward $286.48 — roughly +30% from $270.45. Momentum favours further upside here.
Expect ASND to range from $362.93 to $607.83 through 2028. The $456.52 average target implies a +69% move from current prices. That is up +29% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The ASND price prediction for 2029 points to an average of $516.97 (low $403.82, high $704.69) — a potential gain of +91% on today's $270.45. Momentum favours further upside here.
In 2030, ASND is projected to trade between $428.76 and $775.08, averaging $557.43 — a potential gain of +106% from today's $270.45. That is up +8% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Ascendis Pharma A/S's 2031 outlook centres on $651.42, within a $494.09 to $921.69 range. That is up +17% on the projected 2030 average. That marks a +141% change versus current levels. Momentum favours further upside here.
By 2032, ASND could reach as high as $970.71, with a base case around $675.40 and support toward $505.67 — roughly +150% from $270.45. Buyers look set to stay in control over this stretch.
Expect ASND to range from $542.27 to $1,068.78 through 2033. The $733.11 average target implies a +171% move from current prices. That is up +9% on the projected 2032 average. Momentum favours further upside here.
The ASND price prediction for 2034 points to an average of $930.61 (low $680.51, high $1,374.65) — a potential gain of +244% on today's $270.45. Buyers look set to stay in control over this stretch.
In 2035, ASND is projected to trade between $753.58 and $1,557.94, averaging $1,041.87 — a potential gain of +285% from today's $270.45. That is up +12% on the projected 2034 average. Momentum favours further upside here.
Ascendis Pharma A/S's 2040 outlook centres on $1,516.91, within a $1,044.63 to $2,388.36 range. That is up +46% on the projected 2035 average. That marks a +461% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, ASND could reach as high as $5,504.28, with a base case around $3,239.82 and support toward $2,054.73 — roughly +11.0x from $270.45. Momentum favours further upside here.
Investing $1,000 in ASND today (≈ 3.697541 ASND) could be worth
$11,979.38
+$10,979.38 (+1098%) by 2050 · US Dollar
Based on the average projected ASND price of $3,239.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ASNDwould be worth at today's price.
$1,000 invested in ASND on Jul 10, 2025 (≈ 5.666043 ASND) would be worth
$1,532.38
+$532.38 (+53.2%) today · 1.53× · US Dollar
Based on a ASND entry price of $176.49 vs. today's $270.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $274.5 | $985.25 | -1.5% |
| 1 month ago | $209.79 | $1,289.15 | +28.9% |
| 3 months ago | $239.28 | $1,130.27 | +13.0% |
| 6 months ago | $208.76 | $1,295.51 | +29.6% |
| 1 year ago | $176.49 | $1,532.38 | +53.2% |
| All time (5.0y) ago | $124.52 | $2,171.94 | +117.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ASND forecast.
Our base-case forecast reaches $540.00 around 2030.
Implied market cap at $540.00: $35.42B
The multi-year forecast projects steady upside from 2027 onward, with the 2027 average at $363.10 and ROI of 38.8%, followed by a 2028 average of $471.51 (ROI 80.3%) and a 2029 average of $536.43 (ROI 105.1%). By 2030, the forecast shows an average of $593.04 with an ROI of 126.7% and a bullish sentiment.
Beyond 2030, the trajectory remains bullish, with a 2031 average of $691.08 (ROI 164.2%), 2032 $708.59 (ROI 170.9%), and 2033 $796.20 (ROI 204.4%). The 2040 forecast implies an average of $1,720.40 (ROI 557.7%) and a 2050 average of $3,743.21 (ROI 1,331%), both with bullish sentiment.
These figures are estimates and not guarantees. The forecast reflects potential upside over the long term, but actual results may differ and depend on a range of factors, including market conditions and company-specific developments. The annualized volatility is 50%, indicating a higher level of price movement across the period.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $593.04, a min of $444.68, and a max of $850.82, with an ROI of 126.7% and a bullish sentiment.
Yes. The forecast max prices reach above $1,000 in 2031 ($1,011.43) and 2032 ($1,055.78), with a further rise to $1,205.74 in 2033. The 2031-2033 windows show the potential to exceed $1,000.
Yes. The forecast from 2027 onward is bullish, with rising avg prices and positive ROI: 2027 avg $363.10 (ROI 38.8%), 2028 avg $471.51 (ROI 80.3%), 2029 avg $536.43 (ROI 105.1%), 2030 avg $593.04 (ROI 126.7%), and continuing higher through 2050 (avg $3,743.21, ROI 1,331%).
RSI14 is 70, indicating bullish momentum. SMA50 is $231.49 and SMA200 is $218.62, with a support level at $205.81 and resistance at $261.58. The 30-day range is from $221.31 to $309.18.
The current price is $261.58 and the market cap is $17.15B. The stock ranks 654.
Ascendis Pharma A/S Community Discussion
0Share your Ascendis Pharma A/S price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.